share_log

Seelos Therapeutics | CORRESP: CORRESP

Seelos Therapeutics | CORRESP: CORRESP

Seelos Therapeutics | CORRESP：信函
美股sec公告 ·  03/13 01:02
牛牛AI助理已提取核心訊息
Seelos Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on February 2, 2024, and subsequently amended on March 6, 2024. The company seeks to have the Registration Statement become effective at 4:00 p.m. Eastern Time on March 15, 2024, or as soon as possible thereafter. This Registration Statement pertains to an offering of Seelos Therapeutics' common stock by selling stockholders, and notably, there are no underwriters involved in this offering. The company has confirmed its understanding of and commitment to its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 in relation to this securities offering. Seelos Therapeutics has authorized its outside counsel, Samantha Eldredge of Paul Hastings LLP, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Seelos Therapeutics, Inc. has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on February 2, 2024, and subsequently amended on March 6, 2024. The company seeks to have the Registration Statement become effective at 4:00 p.m. Eastern Time on March 15, 2024, or as soon as possible thereafter. This Registration Statement pertains to an offering of Seelos Therapeutics' common stock by selling stockholders, and notably, there are no underwriters involved in this offering. The company has confirmed its understanding of and commitment to its responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 in relation to this securities offering. Seelos Therapeutics has authorized its outside counsel, Samantha Eldredge of Paul Hastings LLP, to communicate with the SEC regarding the effectiveness of the Registration Statement and to make any necessary modifications or withdrawals to the acceleration request.
Seelos Therapeutics, Inc.已正式要求美國證券交易委員會（SEC）加快其S-1表格註冊聲明的生效，該聲明最初於2024年2月2日提交，隨後於2024年3月6日修訂。該公司力求使註冊聲明於美國東部時間2024年3月15日下午 4:00 生效，或此後儘快生效。本註冊聲明涉及通過出售股東發行Seelos Therapeutics普通股，值得注意的是，本次發行沒有承銷商參與。該公司已確認其對1933年《證券法》和1934年《證券交易法》規定的與本次證券發行有關的責任的理解和承諾。Seelos Therapeutics已授權其外部法律顧問、保羅·黑斯廷斯律師事務所的薩曼莎·埃爾德雷奇就註冊聲明的有效性與美國證券交易委員會進行溝通，並對加速請求進行任何必要的修改或撤回。
Seelos Therapeutics, Inc.已正式要求美國證券交易委員會（SEC）加快其S-1表格註冊聲明的生效，該聲明最初於2024年2月2日提交，隨後於2024年3月6日修訂。該公司力求使註冊聲明於美國東部時間2024年3月15日下午 4:00 生效，或此後儘快生效。本註冊聲明涉及通過出售股東發行Seelos Therapeutics普通股，值得注意的是，本次發行沒有承銷商參與。該公司已確認其對1933年《證券法》和1934年《證券交易法》規定的與本次證券發行有關的責任的理解和承諾。Seelos Therapeutics已授權其外部法律顧問、保羅·黑斯廷斯律師事務所的薩曼莎·埃爾德雷奇就註冊聲明的有效性與美國證券交易委員會進行溝通，並對加速請求進行任何必要的修改或撤回。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。